Animal Blood Plasma Products and Derivatives Market - Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning / Landscape Review & Global Market Size Forecast to 2032
Overview
Global Animal Blood Plasma Products and Derivatives Market size was valued at USD 1.85 Bn. in 2024 and the total Animal Blood Plasma Products and Derivatives Market revenue is expected to grow by 3.8% from 2025 to 2032, reaching nearly USD 2.49 Bn.
Animal Blood Plasma Products and Derivatives Market Overview:
Animal blood plasma products and derivatives are a key biobased product used in various pharmaceutical manufacturing, veterinary medicine, biotechnology research, diagnostics, and animal nutrition. Products such as fetal bovine serum (FBS), albumin, immunoglobulins, and clotting factors are harvested from livestock blood and processed to varying degrees for use in interventions and research. The Animal Blood Plasma Products and Derivatives Market continues to evolve from the historically used serum for cell culture and vaccines to high-purity and ethically sourced, GMP-certified plasma products from livestock for advanced biologics, regenerative medicine and precision veterinary therapies. The demand continues to increase due to the continued growth of biologics, monoclonal antibody production, stem cell therapy and preventive health strategies in animal health. FBS and albumin are important components in biologics production and tissue engineering, while spray-dried plasma is gaining interest in piglet and poultry nutrition in the Asia Pacific region and Latin America.
The Animal Blood Plasma Products and Derivatives Market report covered a comprehensive overview of key market drivers such as new plasma fractionation technologies, biopharmaceutical product manufacture, and ethically sourced regulation. The report also provides analysis of market segments by product type, application, animal source, etc.
The main Key Players within the global Animal Blood Plasma Products and Derivatives Market include Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Proliant Biologicals, Bovogen Biologicals, LAMPIRE Biological Laboratories, Auckland BioSciences, and Kraeber & Co., and the industry value chain analysis companies are developing high purity, traceable, and regionally certified plasma products in response to the demand for cell based therapies, veterinary biologics, and functional feed additives. The report identified trends such as growth of chemically defined serum substitutes, growth of disease-free plasma sourcing (New Zealand, Australia), and ethically sourced high-purity derivatives driven by regulatory demands across global segments.
To know about the Research Methodology :- Request Free Sample Report
Animal Blood Plasma Products and Derivatives Market Dynamics
Rising Demand for Immunoglobulin-Based Biologics and FBS to Drive Animal Blood Plasma Products Market Growth
The growing utilization of animal blood plasma products in the pharmaceutical and diagnostic sectors remains a significant driver for market expansion. Products can generally be divided into immunoglobulins, FBS (fetal bovine serum), albumin, and clotting components, and have significant contributions to vaccine production, monoclonal antibody manufacture, and high-level biologics. FBS is a critical supplement needed to grow mammalian cells in media for basic R&D, and is essential for commercial-scale biomanufacturing. A broad rise in precision therapies, regenerative medicine, and rapid diagnostics will demand high-purity and functionally active plasma products, offering compound annual growth in the pharmaceutical and biotechnology market.
Innovation in Therapeutic Applications and Targeted Delivery to Create Animal Blood Plasma Products Market Opportunities
New advancements in oncology and personalized medicine are creating opportunities to use animal blood plasma derivatives. Many components of animal blood plasma, such as immunoglobulins and serum proteins, have growing research surrounding their use in various cancer applications, including cancer immunotherapy, drug delivery, and targeted therapy. Having the ability to use animal-derived serum proteins as plasma carriers will allow for improved bioavailability and decreased toxicity for the personalized drug regimens being developed for personalized medicine, such as chemotherapy and biologics. Additionally, animal blood plasma contains bioactive components that can be engineered as bioactive components or stabilizers for future therapeutics that are personalized to each patient's needs.
Animal Welfare Regulations and Compliance Complexities to Present Challenges for Animal Blood Plasma Products Market
The issue of animal welfare and the rigid regulatory restrictions hinder the development of the animal blood plasma products market. Regulations are tightly imposed by organizations like the U.S. FDA, the European Medicines Agency (EMA) and other agencies in the EU, which have significant standards and regulations regarding the collection, treatment and use of plasma derived products with specific guidelines centered on fetal bovine serum (FBS), which not only must be ethically collected, but also faces greater scrutiny because of the animal that is used to collect it. In addition to larger application review and approval processes, these requirements are often associated with increased documentation and regulatory compliance costs, particularly for manufacturers involved in a wide range of animal plasma-derived products on the market.
Global Animal Blood Plasma Products and Derivatives Market Segment Analysis
Based on Product Type, the animal blood plasma products and derivatives market is segmented into immunoglobulins, albumin, fibrinogen & clotting factors, fetal bovine serum (FBS), and others. Among these, fetal bovine serum (FBS) segment has dominated the market in 2024 and is expected to hold the largest market share over the forecast period. Because of its nutrient-rich composition and growth-promoting properties, fetal bovine serum is difficult to replace in biological systems and is a necessity for any cell in vitro growth, especially for pharmaceutical and biotechnological research. The growing need for biopharmaceuticals and tissue engineering worldwide continues to support FBS.
Based on Application, the animal blood plasma products and derivatives market is segmented into pharmaceuticals & biologics, animal feed & nutrition, cell culture & research, diagnostics, and cosmetics. Pharmaceuticals & biologics segment has dominated the market in 2024 and is expected to hold the largest market share over the forecast period, due to the vast array of plasma-derived products used in vaccine production, therapeutic protein stabilization, and drug formulation. As the biologics manufacturing industry continues to grow, particularly with monoclonal antibodies and cell therapies, demand in this segment is expected to continue to grow.
Animal Blood Plasma Products and Derivatives Market Regional Insights
North America accounted for 40–45% of the global animal blood plasma products and derivatives market in 2024. The well-established biotechnology and pharmaceutical sectors across North America, and particularly in the United States, are a major factor in the region's performance. The U.S. is a global hub for biologics, vaccines, and regenerative research and is one of the largest consumers and exporters of fetal bovine serum (FBS) due to several factors including the stringent requirements on plasma quality, excellent fractionation facilities and investments in R&D. The region's transparent regulatory incluences, not to mention ongoing demand from veterinary and life sciences continue to make North America a dominant force in the market.
Animal Blood Plasma Products and Derivatives Market Competitive Landscape
The Animal Blood Plasma Products and Derivatives Market has moderate competition in that the major players are investing heavily with a focus on developing high-purity plasma components for pharmaceutical, research, and veterinary purposes. Two top companies, Thermo Fisher Scientific Inc. (USA) and Bovogen Biologicals Pty Ltd. (Australia), dominate this sector. Thermo Fisher's animal origin products have revenue of USD XX million in 2024, via fetal bovine serum (FBS), albumin, and immunoglobulins in cell culture, diagnostics, and vaccine manufacture, among other applications. Bovogen Biologicals has revenue of USD XX million from its specialized bovine plasma products, including FBS, albumin, and serum-based reagents, creating a positive export market from demand in biotech and veterinary markets in Europe and Asia. In comparison, Thermo Fisher has scale, global accessibility, and bioproduction capabilities, while Bovogen has paid attention to high product purity, ethical sourcing from disease-free Australian cattle and targeted customer relationships. Both companies are expanding their production capacity and product line offerings to meet the demand for traceable and high-quality plasma-derived products.
Animal Blood Plasma Products and Derivatives Market Recent Development
• Thermo Fisher Scientific Inc. (U.S.A.) announced, in May 2025, a new application protocol for its Orbitrap Astral Zoom mass spectrometer for comprehensive plasma proteome profiling using the Seer Proteograph ONE workflow supporting high-throughput biomarker discovery directly from plasma.
• Merck KGaA / MilliporeSigma (Germany) announced, in January 2025, the acquisition of HUB Organoids Holding B.V., expanding its next-gen biology portfolio of organoid-based cell culture models for drug response testing, thus adding to its already well-established plasma and cell-culture media lines.
• Auckland BioSciences Ltd. (New Zealand), established a NZ$2 million serum filtration facility in Auckland in 2023, designed to enhance value-added output for vaccine and therapeutic customers around the world; it ranked 1 in Deloitte NZ's Master of Growth Index in 2022.
• Kraeber & Co. GmbH (Germany) reported early in 2025, strong growth in its porcine and bovine plasma feed category, reporting strong growth due to greater adoption arising in the Asia-Pacific livestock nutrition sector that positions the company as a significant plasma feed supplier among major global suppliers.
• Bovogen Biologicals Pty Ltd (Australia), expanded its bovine protein offerings in 2025, with a focus on high-purity bovine lactoferrin and serum albumin for functional food, nutraceuticals, and pharmaceutical use; this is following its acquisition consolidation under ANZCO Foods, which greatly improves traceability and vertical supply chain control.
Animal Blood Plasma Products and Derivatives Market Recent Trends
| Category | Key Trend | Example Product | Market Impact |
| Cell Culture Reagents | Shift toward chemically defined alternatives to minimize batch variability | Thermo Fisher Defined FBS Alternatives (Gibco brand) | Drives innovation in serum-free research while reducing reliance on animal-sourced materials |
| Fetal Bovine Serum (FBS) | Rising demand for certified, disease-free and traceable FBS sources | Auckland BioSciences Certified NZ-Origin FBS | Enhances trust and compliance in biopharma and cell culture applications, especially in EU & US labs |
| Plasma Feed Ingredients | Increased use of spray-dried plasma in livestock feed to boost immunity | Proliant Spray-Dried Bovine Plasma | 15–20% improvement in post-weaning piglet health, spurring adoption in Asia-Pacific and Latin America |
Animal Blood Plasma Products and Derivatives Market Scope: Inquire before buying
| Animal Blood Plasma Products and Derivatives Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2024 | Forecast Period: | 2025-2032 |
| Historical Data: | 2019 to 2024 | Market Size in 2024: | USD 1.85 Bn. |
| Forecast Period 2025 to 2032 CAGR: | 3.8% | Market Size in 2032: | USD 2.49 Bn. |
| Segments Covered: | by Product Type | Fetal Bovine Serum (FBS) Immunoglobulins Albumin Fibrinogen and Clotting Factors Others |
|
| by Application | Pharmaceuticals and Biologics Animal Feed and Nutrition Cell Culture and Research Diagnostics Cosmetics and Personal Care |
||
| by Animal Source | Bovine Porcine Ovine and Others |
||
Animal Blood Plasma Products and Derivatives Market by Region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, and the Rest of APAC)
Middle EAsia & Africa (South Africa, GCC, Nigeria, Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Animal Blood Plasma Products and Derivatives Market Key Players:
North America
1. Lake Immunogenics (United States)
2. Thermo Fisher Scientific (United States)
3. Rocky Mountain Biologicals (United States)
4. LAMPIRE Biological Laboratories (United States)
5. Proliant Biologicals (United States)
Europe
1. Kraeber & Co. GmbH (Germany)
2. Merck KGaA (Germany)
3. MilliporeSigma (Germany)
Asia Pacific
1. Auckland Biosciences (New Zealand)
2. Bovogen Biologicals (Australia)
3. ANZCO Foods (New Zealand)
Frequently Asked Questions:
1. Which region has the largest share in the Global Animal Blood Plasma Products and Derivatives Market?
Ans: The North America region held the highest share in 2024.
2. What is the growth rate of the Global Animal Blood Plasma Products and Derivatives
Market?
Ans: The Global Animal Blood Plasma Products and Derivatives Market is expected to grow at a CAGR of 3.8% during the forecast period 2025-2032.
3. What is the scope of the Global Animal Blood Plasma Products and Derivatives
Market report?
Ans: The Global Animal Blood Plasma Products and Derivatives Market report helps with the PESTEL, PORTER, Recommendations for Investors and leaders, and market estimation for the forecast period.
4. Who are the key players in the Animal Blood Plasma Products and Derivatives
Market?
Ans: The important key players in the Global Animal Blood Plasma Products and Derivatives Market are –Lake Immunogenics (United States), Thermo Fisher Scientific (United States), Rocky Mountain Biologicals (United States), LAMPIRE Biological Laboratories (United States), Proliant Biologicals (United States), etc.
5. What is the study period of Animal Blood Plasma Products and Derivatives Market?
Ans: The Global Animal Blood Plasma Products and Derivatives Market is studied from 2024 to 2032.